Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?
Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z, Mawrin C, Brisch R, Bielau H, Meyer zu Schwabedissen L, Bogerts B, Myint AM. · 2011
Read Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? by Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z, Mawrin C, Brisch R, Bielau H, Meyer zu Schwabedissen L, Bogerts B, Myint AM. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3177898.txt.
Introduction
Johann Steiner and colleagues found a stress-linked brain chemical raised in the brains of severely depressed patients in a 2011 paper in the Journal of Neuroinflammation. Blood immune signals rise during depressive episodes, and brain immune cells may mirror them in a region where signalling by the transmitter glutamate is disturbed in depression. The team stained post-mortem tissue from acutely depressed patients who had died by suicide and from healthy controls.
Cells carrying the chemical, a glutamate-receptor activator made by brain immune cells, were significantly denser in two of three subregions of the cingulate area. The rise traced to major depression specifically, not bipolar disorder. Since blocking that receptor relieves depression fast in trials, an immune-driven excess of its activator offers a fresh disease mechanism and treatment angle.
Catalog record
| CREATOR | Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z, Mawrin C, Brisch R, Bielau H, Meyer zu Schwabedissen L, Bogerts B, Myint AM. |
|---|---|
| YEAR | 2011 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: Evidence for an immune-modulated glutamatergic neurotransmission? By Johann Steiner, Martin Walter, Tomasz Gos, Gilles J Guillemin, Hans-Gert Bernstein, Zoltán Sarnyai, Christian Mawrin, Ralf Brisch, Hendrik Bielau, Louise Meyer zu Schwabedissen, Bernhard Bogerts, Aye-Mu Myint Published in: Journal of Neuroinflammation DOI: 10.1186/1742-2094-8-94 ABSTRACT Abstract Background Immune dysfunction, including monocytosis and increased blood levels of interleukin-1, interleukin-6 and tumour necrosis factor α has been observed during acute episodes of major depression. These peripheral immune processes may be accompanied by microglial activation in subregions of the anterior cingulate cortex where depression-associated alterations of glutamatergic neurotransmission have been described. Methods Microglial immunoreactivity of the N-methyl-D-aspartate (NMDA) glutamate receptor agonist quinolinic acid (QUIN) in the subgenual anterior cingulate cortex (sACC), anterior midcingulate cortex (aMCC) and pregenual anterior cingulate cortex (pACC) of 12 acutely depressed suicidal patients (major depressive disorder/MDD, n = 7; bipolar disorder/BD, n = 5) was analyzed using immunohistochemistry and compared with its expression in 10 healthy control subjects. Results Depressed patients had a significantly increased density of QUIN-positive cells in the sACC (P = 0.003) and the aMCC (P = 0.015) compared to controls. In contrast, counts of QUIN-positive cells in the pACC did not differ between the groups (P = 0.558). Post-hoc tests showed that significant findings were attributed to MDD and were absent in BD. Conclusions These results add a novel link to the immune hypothesis of depression by providing evidence for an upregulation of microglial QUIN in brain regions known to be responsive to infusion of NMDA antagonists such as ketamine. Further work in this area could lead to a greater understanding of the pathophysiology of depressive disorders and pave the way for novel NMDA receptor therapies or immune-modulating strategies. BACKGROUND Recent studies have focused on the role of immune dysfunction in depression, and analogies to "cytokine-induced sickness behavior" have been established [1]. Sickness behavior is a coordinated set of adaptive behavioral changes that develop in affected individuals during the course of an infection. Disease symptoms include lethargy, depression, failure to concentrate, anorexia, sleep disturbances, reduction in personal hygiene or social withdrawal, and are mediated by proinflammatory cytokines, such as interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor α (TNFα) [1]. Previous research has suggested that these specific monocyte-derived cytokines are increased in the peripheral blood of acutely depressed patients [2-7] along with elevated monocyte counts [8,9]. Furthermore, lymphocyte and natural killer cell abnormalities have been described [10-12]. It is not yet clear, whether these changes in the peripheral blood are associated with corresponding neuroinflammatory responses and alterations in neurotransmission. Peripheral immune processes may be mirrored in the brains of patients with acute depression by microglial cells which represent the brain's mononuclear phagocyte system (MPS) [2,13]. Indeed, an increased density of microglia expressing human leukocyte antigen (HLA)-DR has recently been observed in the anterior midcingulate cortex (aMCC), the dorsolateral prefrontal cortex and the mediodorsal thalamus of suicidal patients with affective disorders [14]. However, this study of the surface marker HLA-DR did not suggest a mechanism of how modulation of neurotransmission is accomplished. Quinolinic acid (QUIN), an endogenous modulator with agonistic properties on N-methyl-D-aspartate (NMDA), which is produced by microglial cells, may serve as a potential candidate for such a link between immune and neurotransmitter changes in depression [13]. This hypothesis is based on the observation that the above mentioned proinflammatory cytokines induce a shift from serotonin synthesis to tryptophan metabolism via the kynurenine pathway in glial cells [1,15-17], which may ultimately lead to serotonin depletion and particularly an increased production of the metabolite QUIN (Figure 1). MPS cells, such as microglia, macrophages and monocytes, mainly produce the NMDA receptor agonist QUIN, while astrocytes synthesize the NMDA receptor antagonist kynurenic acid (KYNA) because they lack the enzyme kynurenine monoxygenase (KMO) [18-20]. Analyses of blood and cerebrospinal fluid revealed elevated QUIN levels in cytokine-induced depression and major depressive disorder (MDD) [1,21,22], while an increase in KYNA production was related to schizophrenia [23-25]. [Figure: modified from [13]: Tryptophan is an essential amino acid and a precursor for the synthesis of serotonin. Alternatively, tryptophan can be metabolized in glial cells via the kynurenine pathway to create kynurenic acid (synthesized by kynurenine aminotransferase, KAT) or quinolinic acid (QUIN). These substances are endogenous modulators of NMDA glutamate receptors. A key enzyme of the kynurenine pathway, indoleamine 2,3-dioxygenase (IDO), and the enzyme that catalyses the production of 3-OH-kynurenine, kynurenine monoxygenase (KMO), are activated by proinflammatory cytokines, including interleukin-1 and -6 (IL-1, IL-6), tumor necrosis factor a (TNFa), or interferon g (IFNg). These enzymes are inhibited by anti-inflammatory cytokines, including IL-4. Serotonin is normally broken down into 5-hydroxyindoleacetic acid (5-HIAA), but the indole ring of serotonin can also be cleaved by IDO to form formyl-5-hydroxykynurenamine (f-5-KYM). Annotation: grey arrows: activation; dotted grey lines with bar at the end: inhibition; black font: potentially neurotoxic; purple font: neutral or not known; bright blue: potentially neuroprotective.] These findings may connect immune pathologies to MPS activation in MDD. In addition to serotonin depletion, a direct glutamatergic mechanism has been suggested, which has recently been identified as an important target of antidepressant treatment [26]. In this context, the anterior cingulate cortex (ACC), with its region-specific NMDA and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor profiles that cover functionally segregated areas, represents an important target region in the central nervous system, although investigations must account for the histo-architectural diversity of this region [27]. The importance of the pregenual anterior cingulate cortex (pACC) in MDD is supported by the pronounced effects of the glutamate modulating NMDA antagonist ketamine on the improvement of clinical symptoms in treatment-resistant MDD patients [28], in which ketamine leads to an increase in glutamate concentration precisely in this region [29]. Therefore, we hypothesized that brain region-specific QUIN synthesis increases in depression and investigated this idea by analyzing the cellular and regional focus of QUIN immunoreactivity in the ACC of depressed suicidal MDD and bipolar disorder (BD) patients. An upregulated production of QUIN by microglia in regions with specific susceptibility to abnormal NMDA throughput would support the hypothesis of an upregulated MPS, and would close the gap between neurochemical imbalances and regional as well as functional in vivo imaging findings in depression. Only acutely ill patients were selected for the study, as previous studies of peripheral blood indicate that MPS activation and kynurenine pathway imbalances are associated with acute disease phases. In a postmortem study of chronically stable patients with MDD or BD, transient microglial changes may be missed. METHODS Human brain tissue Postmortem brains were obtained from the Magdeburg brain bank in accordance with the Declaration of Helsinki and the local institutional review board. Written consent was obtained from the next of kin. The donors were acutely depressed patients (n = 12) who had committed suicide (mean age 51 years; 6 males, 6 females) and controls (n = 10) with no neuropsychiatric illness (mean age 56 years; 5 males, 5 females). The cases were matched with respect to age, gender, duration of disease and autolysis time (Table 1). Patients had been diagnosed with either major depressive disorder (MDD; n = 7) or bipolar disorder (BD; n = 5). [Table: Demographic data of patients with depression (n